<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM) is a progressive disease characterized by worsening <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Lowering <z:chebi fb="34" ids="35143">haemoglobin</z:chebi> A1c to below or around 7% has been shown to reduce microvascular and neuropathic complications of <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>The ongoing uncertainty regarding whether intensive glycaemic control can reduce the increased risk of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) in people with T2DM stirred the launch of the recent long-term megatrials </plain></SENT>
<SENT sid="3" pm="."><plain>These trials compared the effects of intensive vs. standard control on vascular complications in relatively high CV risk participants with T2DM </plain></SENT>
<SENT sid="4" pm="."><plain>While in Veterans Affairs <z:mp ids='MP_0002055'>Diabetes</z:mp> Trial, and Action to Control Cardiovascular Risk in <z:mp ids='MP_0002055'>Diabetes</z:mp>, the effect of <z:chebi fb="105" ids="17234">glucose</z:chebi> optimization resulted either in no protection or in an excessive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> <z:hpo ids='HP_0011420'>death</z:hpo>, the Action in <z:mp ids='MP_0002055'>Diabetes</z:mp> and <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">Vascular Disease</z:e>: Preterax and Diamicron Modified Release Controlled Evaluation trial showed that intensive glycaemic control reduced the risk of combined major macrovascular and microvascular events </plain></SENT>
<SENT sid="5" pm="."><plain>In this trial, the <z:chebi fb="105" ids="17234">glucose</z:chebi> control strategy was based on <z:chebi fb="0" ids="31654">gliclazide</z:chebi> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> at randomization in <z:hpo ids='HP_0000001'>all</z:hpo> patients and then further sequential addition of other <z:chebi fb="105" ids="17234">glucose</z:chebi>-lowering drugs </plain></SENT>
<SENT sid="6" pm="."><plain>Several studies showed that <z:chebi fb="0" ids="31654">gliclazide</z:chebi> has <z:chebi fb="11" ids="22586">antioxidant</z:chebi> properties, reduces markers of endothelial <z:mp ids='MP_0001845'>inflammation</z:mp>, and prevents <z:chebi fb="105" ids="17234">glucose</z:chebi>-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> of endothelial cells </plain></SENT>
<SENT sid="7" pm="."><plain>These positive <z:chebi fb="11" ids="22586">antioxidant</z:chebi> effects are not confined to the vascular wall but they are effective also in the Î² cells </plain></SENT>
<SENT sid="8" pm="."><plain>These properties are important because (i) in patients with atherosclerotic process, microvascular abnormalities may hasten disease progression and (ii) slowing the microvascular complications may have a potentially remarkable effect on the natural history of macrovascular disease </plain></SENT>
</text></document>